# Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

> **NCT05921006** · PHASE1 · UNKNOWN · sponsor: **Nanjing Ruijie Pharma Co., Ltd.** · enrollment: 98 (estimated)

## Conditions studied

- Drug Safety

## Interventions

- **DRUG:** RJ4287
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05921006
- **Lead sponsor:** Nanjing Ruijie Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-13
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05921006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05921006, "Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05921006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*